The nuclear matrix as a target for cancer therapy

Annals of Oncology

Volumn 7, Issue 7, 1996, Pages 659-666

  Catapano, C V ^a   Carbone, G M R ^a   Fernandes, D J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer therapy; DNA primase; Matrix attachment regions; Nuclear matrix; Topoisomerase II

Indexed keywords

AMSACRINE; APHIDICOLIN; CYTARABINE; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUDARABINE PHOSPHATE; MIZORIBINE; MYCOPHENOLIC ACID; TENIPOSIDE;

CANCER CHEMOTHERAPY; CELL NUCLEUS MATRIX; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029810970     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010713     Document Type: Review

References (90)

1. Berezney R. The nuclear matrix: A heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 1991; 47: 109-23.
2. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974; 60: 1410-7.
3. Fernandes DJ, Smith-Nanni C, Paff MT et al. Effects of anti-leukemic agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cell. Cancer Res 1989; 48: 1850-5.
4. Getzenberg RH, Pienta KJ, Ward WS et al. Nuclear structure and three-dimensional organization of DNA. J Cell Biochem 1991; 47: 289-99.
5. Stein GS, Lian JB, Dworetzky SI et al. Regulation of transcription-factor activity during growth and differentiation: Involvement of the nuclear matrix in concentration and localization of promoter binding proteins. J Cell Biochem 1991; 47: 300-5.
6. Cook PR. The nucleoskeleton and the topology of replication. Cell 1991; 66: 627-35.
7. Xing Y, Johnson CV, Dobner PR et al. Higher level organization of individual gene transcription and RNA splicing. Science 1993; 259: 1326-30.
8. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 1989; 49: 2525-32.
9. Nelson WG, Pienta KJ, Barrack ER et al. The role of the nuclear matrix in the organization and function of DNA. Ann Rev Biophys Biochem 1986; 15: 457-75.
10. Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher order chromatin loop: Specific DNA attachment sites on nuclear scaffold. Cell 1984; 39: 223-32.
11. Gasser SM, Laroche R, Falquet J et al. Metaphase chromosome structure: Involvement of topoisomerase II. J Mol Biol 1986; 188: 613-29.
12. Kas E, Izaurralde E, Laemmli UK. Specific inhibition of DNA binding to nuclear scaffolds and histone H1 by distamycin. The role of oligo(dA).oligo(dT) tracts. J Mol Biol 1989; 210: 587-99.
13. Bode J, Kohwi Y, Dickinson L et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 1992; 255: 195-7.
14. Adachi Y, Kas E, Laemmli UK. Preferential cooperative binding of DNA topoisomerase II to scaffold-association regions. EMBO J 1989; 8: 3997-4006.
15. Von Kries JP, Buhrmester H, Strätling WH. A matrix/scaffold attachment region binding protein: Identification, purification, and mode of binding. Cell 1991; 6: 123-35.
16. Romig H, Fackelmayer FO, Renz A et al. Characterization of SAF-A, a novel nuclear DNA binding protein from HeLa cells with high affinity for nuclear matrix/scaffold attachment DNA elements. EMBO J 1992; 11: 3431-40.
17. Tsutsui K, Tsutsui K, Okada S et al. Identification and characterization of a nuclear scaffold protein that binds the matrix attachment region DNA. J Biol Chem 1993; 268: 12886-94.
18. Bonifer C, Hecht A, Saueressig H et al. Dynamic chromatin: The regulatory domain organization of eukaryotic gene loci. J Cell Biol 1991; 47: 99-108.
19. Stief A, Winter DM, Strätling WH et al. A nuclear DNA attachment element mediates elevated and position-independent gene activity. Nature 1989; 341: 343-5.
20. Bonifer C, Vidal M, Grosveld F. Tissue specific and position independent expression of the complete gene domain for chicken lysozyme in transgenic mice. EMBO J 1990; 9: 2843-8.
21. Dworetzky SI, Wright KL, Fey EG et al. Sequence-specific DNA-binding proteins are components of a nuclear matrix-attachment site. Proc Natl Acad Sci USA 1992; 89: 4178-82.
22. Bidwell JP, van Wijnen AJ, Fey EG et al. Osteocalcin gene promoter-binding factors are tissue-specific nuclear matrix components. Proc Natl Acad Sci USA 1993; 90: 3162-6.
23. Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eucaryotic cells. Cell 1980; 19: 527-36.
24. Vogelstein B, Pardoll DM, Coffey DS. Supercoiled loops and eucaryotic DNA replication. Cell 1980; 22: 79-85.
25. Nakayasu H, Berezney R. Mapping replicational sites in the eucaryotic cell nucleus. J Cell Biol 1989; 108: 1-11.
26. Hozák P, Hassan AB, Jackson DA. Visualization of replication factors attached to a nucleoskeleton. Cell 1993; 73: 361-73.
27. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: Cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 1993; 74: 979-92.
28. Pienta JK, Ward WS. An unstable nuclear matrix may contribute to genetic instability. Medical Hypoth 1993; 42: 45-52.
29. Partin AW, Getzenberg RH, CarMichael MJ et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993; 53: 744-6.
30. Khanuja PS, Leher JE, Soule HD. Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 1993; 53: 3394-8.
31. Mittnacht S, Weinberg RA. G1/S phosphorilation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 1991; 65: 381-93.
32. Mancini AM, Shan B, Nickerson JA. The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci 1994; 91: 418-22.
33. Grignani F, Ferrucci PF, Testa U et al. The acute promyelocitic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-31.
34. Dyck JA, Maul GG, Miller WH et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-4.
35. Weis K, Rambaud S, Lavau C et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR α in acute promyelocytic leukemia cells. Cell 1994; 76: 345-56.
36. Chang KS, Fan Y-H, Andreef M et al. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 1995; 85: 3646-53.
37. Kohn KW. Interstand cross-linking of DNA by 1,3-bis(2-chlorethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 1977; 37: 1450-4.
38. 6-alkylguanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279-92.
39. Tew KD. The interaction of nuclear reactant drugs with the nuclear membrane and nuclear matrix. In Maul GG (ed): The Nuclear Envelope and the Nuclear Matrix. New York: Alan R. Liss, Inc. 1982; 279-92.
40. Tew KD, Wang AL, Schein PS. Alkylating agent interactions with the nuclear matrix. Biochem Pharmacol 1983; 32: 3509-16.
41. Tew K, Erickson L, White G et al. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol Pharmacol 1983; 24: 324-8.
42. Tew KD, Stearns ME. Hormone-independent, non alkylating mechanism of cytotoxicity for estramustine. Urol Res 1987; 15: 155-60.
43. Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986; 9: 387.
44. Pienta K, Lehr J. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 1993; 149: 1622-5.
45. Pienta KJ, Redman B. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12.
46. Pienta KJ, Redman BG, Maha-Hussain DO. Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 1995; 75: 1920-6.
47. Chiu S-M, Friedman LR, Sokany NM et al. Nuclear matrix proteins are crosslinked to transcriptionally active gene sequences by ionizing radiation. Radiat Res 1986; 107: 24-38.
48. Chiu S-M, Xue LY, Friedman LR et al. Chromatin compaction and the efficiency of formation of DNA-protein crosslinks in gamma-irradiated mammalian cells. Radiat Res 1992; 129: 184-91.
49. Olenick NL, Chiu S-M, Ramakrishnan N et al. The formation, identification, and significance of DNA-protein cross-links in mammalian cells. Br J Cancer 1987: 8: 135-40.
50. Chiu S-M, Xue L-Y, Friedman L et al. Copper ion-mediated sensitization of nuclear matrix attachment sites to ionizing radiation. Biochemistry 1993; 32: 6214-9.
51. Vaughan A, Milner T, Gordon D et al. Interaction between ionizing radiation and supercoiled DNA within human tumour cells. Cancer Res 1991; 51: 3857-61.
52. Milner A, Gordon D, Turner B et al. A correlation between DNA-nuclear matrix binding and relative radiosensitivity in two human squamous cell carcinoma cell line. Int J Radiat Biol 1993; 63: 13-20.
53. Paff MT, Fernandes DJ. Synthesis and distribution of primer RNA in nuclei of CCRF-CEM leukemia cells. Biochemistry 1990; 29: 3442-50.
54. Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res 1991; 51: 1829-35.
55. Tseng WC, Derse D, Cheng YC et al. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerase and ribonucleotide resuctase from HeLa cells. Mol Pharmacol 1982; 21: 474-7.
56. Parker WB, Bapat AR, Shen JX et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerase, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1982; 34: 485-91.
57. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl 2-fluoroadenine: A mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617-25.
58. Parker WB, Cheng Y-C. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol 1987; 31: 146-51.
59. Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-triphosphate: A mechanism of DNA synthesis inhibition. J Biol Chem 1993; 268: 7179-85.
60. Yang SW, Huang P, Plunkett W et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992; 267: 2345-9.
61. Fernandes DJ, Wang L-M, Catapano CV. Inhibition of gene amplification and drug resistance by fludarabine phosphate. Proc Am Assoc Cancer Res 1995; 36: 443.
62. Lowe JK, Brox L, Henderson JF. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res 1977; 37: 736-43.
63. Tricott GJ, Jayaram HN, Lapis E et al. Biochemically directed therapy of leukemia with tiazofurin, selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res 1989; 49: 3696-701.
64. Turka LA, Dayton J, Sinclair G et al. Guanine ribonucleotide depletion inhibits T-cell activation: Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 1991; 87: 940-8.
65. Catapano CV, Dayton JS, Mitchell BS et al. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol 1995; 47: 948-55.
66. Kaguni LS, Lehman IR. Eukaryotic DNA polymerase-primase: Structure, mechanism and function. Biochem Biophys Acta 1988; 950: 87-101.
67. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270: 21429-32.
68. Fernandes DJ, Catapano CV. Nuclear matrix targets for anti-cancer agents. Cancer Cells 1991; 262: 5857-65.
69. Nelson WG, Liu LF, Coffey DS. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 1986; 322: 187-9.
70. Woynarowski JM, Sigmund RD, Beerman TA. Topoisomerase-II-mediated lesions in nascent DNA: Comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA. Biochim Biophys Acta 1988; 950: 21-9.
71. Kaufmann WK, Boyer JC, Estabrooks LL et al. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 1991; 11: 3711-8.
72. Catapano CV, Pisani FD, Fernandes DJ. Topoisomerase II-DNA complexes stabilized by VM-26 block DNA chain elongation in human leukemia CEM cells. Proc Am Assoc Cancer Res 1994; 35: 458.
73. Catapano CV, Carbone GMR, Hatcher H et al. Arrest of replication fork progression at topoisomerase II-mediated DNA cleavage sites in human leukemia CEM cells treated with VM-26. Proc Am Assoc Cancer Res 1995; 36: 443.
74. Berrios M, Osheroff N, Fisher PA. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 1985; 82: 4142-6.
75. Earnshaw WC, Halligan WB, Cooke CA et al. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 1985; 100: 1706-15.
76. Danks MK, Qiu J, Catapano CV et al. Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol 1994; 48: 1785-95.
77. Qiu J, Catapano CV, Fernandes DJ. Cytotoxicity of VM-26 is associated with the formation of drug-stabilized topoisomerase II α complexes with nascent DNA. Proc Am Assoc Cancer Res 1996; 37: 434.
78. Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 1990; 29: 4235-41.
79. Filipski J, Leblanc J, Youdale T. Periodicity of DNA folding in higher order chromatin structures. EMBO J 1990; 9: 1319-27.
80. Walker PR, Smith C, Youdale T et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991; 51: 1078-85.
81. Gromova II, Thomsen B, Razin SV. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-myc gene locus in living cells and in high-salt extracted nuclei. Proc Natl Acad Sci USA 1995; 92: 102-6.
82. Sperry AO, Blasquez VC, Garrard WT. Dysfunction of chromosomal loop attachment sites: Illegitimate recombination linked to matrix association regions and topoisomerase II. Proc Natl Acad Sci USA 1989; 86: 5497-501.
83. Han Y-H, Finley-Austin MJ, Pommier Y et al. Small deletion and insertion mutation induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J Mol Biol 1993; 229: 52-66.
84. Pommier Y, Zwelling LA, Kao-Shan C-S et al. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in chinese hamster cells. Cancer Res 1985; 45: 3143-9.
85. Berger NA, Chatterjee S, Schmotzer JA et al. Etoposide (VP-16-213)-induced gene alterations: Potential contribution to cell death. Proc Natl Acad Sci USA 1991; 88: 8740-3.
86. Ratain MJ, Kaminer LS, Bitrain JD et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small carcinoma of the lung. Blood 1987; 70: 1412-7.
87. Luderus ME, den Blaauwen JL, de Smit OJB et al. Binding of matrix attachment regions to lamin polymers involves single-stranded regions and the minor groove. Mol Cell Biol 1994; 14: 6297-305.
88. Kas E, Poljak L, Adachi Y et al. A model for chromatin opening: Stimulation of topoisomerase II and restriction enzyme cleavage of chromatin by distamycin. EMBO J 1993; 12: 115-26.
89. Broggini M, Erba E, Ponti M et al. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res 1991; 51: 199-204.
90. Broggini M, Coley M, Mongelli N et al. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acid Res 1995; 23: 81-7.